 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Biostrophin is a drug which may serve as a vehicle for gene therapy, in the treatment of Duchenne and Becker muscular dystrophy.
As mutations in the gene which codes for the protein dystrophin is the underlying defect responsible for both disorders, biostrophin will deliver a genetically-engineered, functional copy of the gene at the molecular level to affected muscle cells. Dosage, as well as a viable means for systemic release of the drug in patients, is currently being investigated with the use of both canine and primate animal models.
Biostrophin is being manufactured by Asklepios BioPharmaceuticals, Inc., with funding provided by the Muscular Dystrophy Association.
See also
Other drugs for Duchenne muscular dystrophy
- Ataluren
- Rimeporide (experimental)
References
- ^ Khurdayan VK, Bozzo J, Prous JR (Oct 2005). "Chronicles in drug discovery". Drug News & Perspectives. 18 (8): 517–522. doi:10.1358/dnp.2005.18.8.953409. ISSN 0214-0934. PMID 16391721.
- http://www.ncbiotech.org/news_and_events/industry_news/duchenne.html Dec 2006 Archived October 17, 2007, at the Wayback Machine
- "Asklepios Biopharmaceutical, Inc. Announces Cross License with GlaxoSmithKline". 2006-09-28.
External links
 | This drug article relating to the musculoskeletal system is a stub. You can help Misplaced Pages by expanding it. |
 | This genetics article is a stub. You can help Misplaced Pages by expanding it. |
 | This article about biological engineering is a stub. You can help Misplaced Pages by expanding it. |